Caplyta Starting Dose
The recommended starting dose of Caplyta (lumateperone) is 42 mg once daily, taken orally with or without food, and no dose titration is required. 111
Standard Dosing
- 42 mg once daily is the FDA-approved starting and maintenance dose for both schizophrenia and bipolar depression 111
- Can be taken with or without food 1
- No titration needed - start at full therapeutic dose immediately 12
Dose Adjustments Required in Specific Situations
Hepatic Impairment
Drug Interactions with CYP3A4 Inhibitors
- Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): 10.5 mg once daily 11
- Moderate CYP3A4 inhibitors (e.g., diltiazem, fluconazole): 21 mg once daily 11
CYP3A4 Inducers
- Avoid concomitant use with CYP3A4 inducers entirely 1
Clinical Context
The straightforward dosing of Caplyta represents a practical advantage over many other antipsychotics. Multiple recent trials consistently demonstrate efficacy at the 42 mg dose across schizophrenia 2, bipolar depression 345, and as adjunctive therapy in major depressive disorder 67. The lack of titration requirement simplifies initiation and may improve early adherence.
Common adverse effects at 42 mg include: somnolence/sedation (most common), dry mouth, dizziness, nausea, and fatigue 1365. These are generally mild to moderate in severity 4. Notably, lumateperone shows minimal extrapyramidal symptoms, low metabolic risk, and minimal weight gain compared to other atypicals 645.